{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:11:13Z","timestamp":1780315873542,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jpet.2025.103534","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:31:29Z","timestamp":1741239089000},"page":"103534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Discovery of ZYDG2: A potent, selective, and safe GPR40 agonist for treatment of type 2 diabetes"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5730-1435","authenticated-orcid":false,"given":"Mukul R.","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0063-5738","authenticated-orcid":false,"given":"Suresh R.","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitrang J.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibhuti B.","family":"Bhoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshyaya Chandan","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan M.","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debdutta","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Ramdhave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8398-1507","authenticated-orcid":false,"given":"Gautam D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh Kumar","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit C.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2025.103534_bib1","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1021\/acsmedchemlett.6b00331","article-title":"Identification of an orally efficacious GPR40\/FFAR1 receptor agonist","volume":"7","author":"Agarwal","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jpet.2025.103534_bib2","doi-asserted-by":"crossref","first-page":"11303","DOI":"10.1074\/jbc.M211495200","article-title":"The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids","volume":"278","author":"Briscoe","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jpet.2025.103534_bib3","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(11)61879-5","article-title":"TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"379","author":"Burant","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jpet.2025.103534_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1573399810666140214093600","article-title":"Assessment of pancreatic \u03b2-cell function: review of methods and clinical applications","volume":"10","author":"Cersosimo","year":"2014","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.jpet.2025.103534_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fendo.2017.00006","article-title":"Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management","volume":"8","author":"Chaudhury","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jpet.2025.103534_bib6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1021\/ml4000673","article-title":"Discovery of TUG-770: a highly potent free fatty acid receptor 1 (FFA1\/GPR40) agonist for treatment of type 2 diabetes","volume":"4","author":"Christiansen","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jpet.2025.103534_bib7","unstructured":"Desai RC and Srivastava BK (2019) inventors, Zydus Lifesciences limited, assignee. Heterocyclic compounds, U.S. patent 10246470. 2019 Apr\u00a002."},{"key":"10.1016\/j.jpet.2025.103534_bib8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbrc.2006.12.193","article-title":"GPR40 is expressed in glucagon producing cells and affects glucagon secretion","volume":"354","author":"Flodgren","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jpet.2025.103534_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(99)00141-7","article-title":"Glucose-dependent insulinotropic effects of JTT-608, a novel antidiabetic compound","volume":"371","author":"Furukawa","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpet.2025.103534_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2050-6511-14-28","article-title":"Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats","volume":"14","author":"Gowda","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.jpet.2025.103534_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1124\/jpet.115.230730","article-title":"Fasiglifam\/TAK-875, a selective GPR40 agonist, improves hyperglycemia in rats unresponsive to sulfonylureas and acts additively with sulfonylureas","volume":"357","author":"Ito","year":"2016","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103534_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature01478","article-title":"Free fatty acids regulate insulin secretion from pancreatic \u03b2 cells through GPR40","volume":"422","author":"Itoh","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2025.103534_bib13","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1517\/14656566.2013.851668","article-title":"Fasiglifam as a new potential treatment option for patients with type 2 diabetes","volume":"14","author":"Kaku","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jpet.2025.103534_bib14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2337\/dc12-0872","article-title":"Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes","volume":"36","author":"Kaku","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jpet.2025.103534_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4196\/kjpp.2015.19.2.141","article-title":"Differential gene expression in GPR40-overexpressing pancreatic \u03b2-cells treated with linoleic acid","volume":"19","author":"Kim","year":"2015","journal-title":"Korean J Physiol Pharmacol"},{"key":"10.1016\/j.jpet.2025.103534_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/clpt.2012.79","article-title":"A\u00a0perspective on efflux transport proteins in the liver","volume":"92","author":"K\u00f6ck","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpet.2025.103534_bib17","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1124\/dmd.115.064121","article-title":"Fasiglifam (TAK-875) inhibits hepatobiliary transporters: a possible factor contributing to fasiglifam-induced liver injury","volume":"43","author":"Li","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jpet.2025.103534_bib18","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/13543784.2016.1189530","article-title":"Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development","volume":"25","author":"Li","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jpet.2025.103534_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0027270","article-title":"AMG 837: a novel GPR40\/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents","volume":"6","author":"Lin","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jpet.2025.103534_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0046300","article-title":"A\u00a0potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents","volume":"7","author":"Luo","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jpet.2025.103534_bib28","doi-asserted-by":"crossref","first-page":"27118","DOI":"10.1074\/jbc.273.42.27118","article-title":"Specific involvement of G proteins in regulation of serum response factor-mediated gene transcription by different receptors","volume":"273","author":"Mao","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jpet.2025.103534_bib21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1021\/ml1000855","article-title":"Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist","volume":"1","author":"Negoro","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jpet.2025.103534_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186033","article-title":"GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent","volume":"12","author":"Pachanski","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jpet.2025.103534_bib23","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2165\/00003495-200464120-00006","article-title":"The role of sulphonylureas in the management of type 2 diabetes mellitus","volume":"64","author":"Rendell","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.jpet.2025.103534_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2050-6511-15-19","article-title":"CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in N-STZ rats and in islets from type 2 diabetic patients","volume":"15","author":"Sunil","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.jpet.2025.103534_bib25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1124\/jpet.113.206466","article-title":"Chronic treatment with novel gpr40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion","volume":"346","author":"Tanaka","year":"2013","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103534_bib26","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s00125-006-0193-8","article-title":"Expression of the gene for a membrane-bound fatty acid receptor in the pancreas and islet cell tumours in humans: evidence for GPR40 expression in pancreatic beta cells and implications for insulin secretion","volume":"49","author":"Tomita","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.jpet.2025.103534_bib27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.111.183772","article-title":"TAK-875, an orally available G protein-coupled receptor 40\/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats","volume":"339","author":"Tsujihata","year":"2011","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103534_bib29","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.2337\/diabetes.53.suppl_3.S215","article-title":"The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes","volume":"53 Suppl 3","author":"Winzell","year":"2004","journal-title":"Diabetes"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525397478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525397478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:31:19Z","timestamp":1762209079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525397478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0022356525397478"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103534","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of ZYDG2: A potent, selective, and safe GPR40 agonist for treatment of type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103534"}}